WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 75

Legislative bill overview

HB 75 relates to the regulation and use of undesignated glucagon, a medication used to treat severe hypoglycemia (dangerously low blood sugar). The bill likely addresses whether glucagon can be dispensed or administered without a specific patient prescription, similar to how some states have authorized over-the-counter access to glucagon products. The bill is currently in the House Health Services Committee.

Why is this important

Glucagon is a life-saving medication for people with diabetes experiencing severe low blood sugar episodes. Making undesignated glucagon more accessible could allow bystanders, family members, or public spaces (schools, workplaces) to administer it quickly without waiting for emergency services or a specific prescription. Faster access in emergencies can prevent serious complications including seizures, loss of consciousness, or death.

Potential points of contention

  • Scope of access: Whether undesignated glucagon should be available in schools, workplaces, and public settings versus only to household members of diabetic individuals
  • Regulatory framework: How to establish safeguards for proper storage, expiration, and usage instructions while maintaining accessibility
  • Pharmacy and prescriber liability: Questions about liability protection for pharmacists dispensing without a specific patient prescription and for bystanders administering the medication in emergencies

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.